Neuphoria Therapeutics Inc.
NEUPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNeuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. At a $18.6M market cap, Neuphoria Therapeutics Inc. ranks as a micro-cap company within healthcare. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Market Cap
$18.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-1.40
EPS (TTM)
$-3.06
EPS (Fwd)
$-2.46
ROE
-61.7%
ROA
-19.7%
Cash
$19.9M
Total Debt
$34,345
Free CF
-$8.3M
52W Change
-24.1%
Annual Financials
Cash vs Debt
Where NEUP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NEUP finished 21.00% below its 150-day moving average ($4.19) and 21.00% below its 200-day moving average ($4.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NEUP overbought or oversold?
At the October 20, 2026 close, NEUP's RSI(14) was 27.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $19.9M in cash comfortably exceeding the $34K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$8.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -61.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NEUP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.